Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International, Inc. (CCEL) is a NYSE American–listed company focused on cellular processing, cryogenic storage, and cord blood banking. The company describes itself as the world’s first private cord blood bank to separate and store stem cells, with operations that span private cord blood and cord tissue banking, a public cord blood banking program in partnership with Duke University, and technology and biostorage offerings such as PrepaCyte-CB and ExtraVault.
This news page aggregates company-issued updates and regulatory disclosures that affect Cryo-Cell’s business and capital structure. Readers can follow periodic financial results, where the company breaks out revenue from processing and storage fees, public banking activities, and product revenue. Dividend-related announcements are also a recurring theme, including the initiation of regular quarterly cash dividends, changes in dividend levels, and decisions not to declare dividends in certain quarters, often linked to profitability, capital requirements, and strategic priorities.
In addition to earnings and dividend news, Cryo-Cell’s releases highlight developments tied to its license agreement with Duke University, research and development spending related to clinical studies and manufacturing capabilities, and the launch and positioning of ExtraVault for biostorage and distribution services. Disclosures about strategic reviews, such as the pause of initiatives relating to a possible sale or merger of the company, provide further context on corporate strategy.
Investors and observers who want to monitor how Cryo-Cell’s cord blood banking operations, cellular therapy ambitions, and biostorage services evolve over time can use this page to review a chronological record of earnings releases, dividend decisions, strategic updates, and other material announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cryo-Cell International, Inc. (CCEL) announced its fiscal first-quarter results for the period ending February 28, 2023. The company reported revenues of
Net income for the quarter was approximately
Cryo-Cell International (CCEL) reported fiscal 2022 results with consolidated revenues of $30.3 million, up from $28.9 million in fiscal 2021. Processing and storage fees led revenue at $29.8 million. Net income grew to $2.8 million or $0.33 per share, compared to $2.1 million or $0.26 per share in 2021. Key factors included a 5% increase in revenue and a 2% decrease in the cost of sales. The company continues to expand services, including a partnership with Duke University and the launch of ExtraVault, enhancing its biostorage capabilities.
Cryo-Cell International (CCEL) reported a 3% revenue increase in Q3 2022, reaching $7.7 million, compared to $7.5 million in Q3 2021. Processing and storage fees accounted for the majority at $7.5 million. However, net income decreased to $467,000 ($0.06 per share) from $857,000 ($0.10 per share) year-over-year. Cost of sales fell by 4%, while SG&A expenses rose by 3%. The company highlights its partnerships and advanced processing technologies as core strengths.
Cryo-Cell International, Inc. (CCEL) has announced a special cash dividend of $0.90 per share for shareholders of record as of September 2, 2022. The decision reflects the Board's commitment to reward long-term investors while advancing its cellular therapies using cord blood and tissue. Founded in 1989, Cryo-Cell is renowned as the first private cord blood bank and has handled over 500,000 samples globally. The company also engages in clinical applications and has partnered with Duke University for public banking.
Cryo-Cell International, Inc. (CCEL) will transition its stock listing from the Nasdaq Capital Market to the NYSE American on August 30, 2022. Chairman David Portnoy believes this move will enhance trading liquidity for shareholders. The last trading date on Nasdaq is expected to be August 29, 2022. Founded in 1989, Cryo-Cell is renowned for being the first private cord blood bank, with over 500,000 parents utilizing its services globally. The company holds numerous accreditations and a partnership with Duke University, emphasizing its commitment to advanced cellular therapies.
FAQ
What is the current stock price of Cryo-Cell Intl (CCEL)?
What is the market cap of Cryo-Cell Intl (CCEL)?
